The week in 60 seconds
What happened, and nothing elseTechnology fell 4.3 percent and the average stock still rose.
- The S&P 500 fell 0.27 percent while the equal weight version rose 1.48 percent, the widest gap in favor of the average stock this newsletter has recorded.
- Technology lost 4.34 percent and was the only badly negative sector, while ten of eleven sectors rose, led by health care at 5.37 percent.
- The companies that must borrow to build artificial intelligence capacity fell hardest, Dell 17.61 percent and Super Micro 17.96 percent, while Microsoft and Meta both rose.
- September inflation came in hotter than expected on October 14, and long Treasury yields fell anyway, which is a flight from equity risk rather than disinflation.
- The Russell 2000 fell 0.96 percent, so money left the biggest names and stopped at the edge of the index instead of going down the scale.
You have the headline. The brief adds the market setup behind it, a line on each of the five, and what matters next. Continue to the 5-minute brief →
The 5-minute brief
~5 minMarket read
Both of these are true about the same week, and holding them together is the whole lesson. The S&P 500 slipped 0.27 percent from the October 8 close to the October 15 close, the Nasdaq Composite lost 1.77 percent, and if that is all you saw you would call it a soft week. The equal weight S&P 500 rose 1.48 percent, ten of eleven sectors finished higher, and health care had its best week of the year on the way to a record. The reason both descriptions fit is arithmetic: technology carries roughly a third of the cap weighted index, and technology fell 4.34 percent, so one sector was heavy enough to drag the headline down while almost everything else went up. What got sold inside that sector is the part worth your attention. It was not artificial intelligence as an idea. Dell fell 17.61 percent, Super Micro 17.96 percent, Hewlett Packard Enterprise 17.42 percent, Arista 12.03 percent and Vertiv 11.89 percent, and those are the companies that have to raise capital to build the capacity. Microsoft rose 3.22 percent and Meta rose 2.20 percent in the same five sessions, and those are the companies paying for it out of operating cash flow. A market that had given up on artificial intelligence would have sold both. This market sold one. It repriced who writes the cheque, not whether the data centre gets built, and that distinction is the only thing I think is genuinely new this week. One more thing about this week that I would rather tell you than let you discover: four of my five picks made most of their gain in a single session, October 15, which is the day the whole rotation landed at once. Only Crown Castle moved on its own news, on October 9. The other four had real company news earlier in the week that the market largely ignored until it decided to reprice everything together. All four still beat their own sectors on the day, by three to four points each in the case of Kimberly-Clark and BlackRock, so the news mattered. But the week is a reminder that a flow can decide when your reasons get paid.
Market Risk Score: 58 / 100 (Neutral).
The risk score grades overall market conditions from 0 (calm) to 100 (high risk). It sets how cautious the week's read is. It is not a signal to buy or sell anything.
The five
- 01CCI, view score cardCrown Castle Inc.Spectrum DealWeekly moveup 16.1 percent
It made the five because the evidence rules out the easy alternative explanation, and because it is the only one of these five that moved on its own news rather than on the rotation.
- 02UNH, view score cardUnitedHealth Group IncorporatedRaised OutlookWeekly moveup 9.6 percent
It made the five because the attribution survives the obvious objection.
- 03REGN, view score cardRegeneron Pharmaceuticals, Inc.Trial ExtensionWeekly moveup 7.7 percent
It made the five on the strength of the result rather than the strength of the attribution, and I want to be precise about which, because this is the weakest case in the issue.
- 04KMB, view score cardKimberly-Clark CorporationMerger ClearedWeekly moveup 6.5 percent
It made the five because of what that delayed reaction looks like when you measure it properly.
- 05BLK, view score cardBlackRock, Inc.Record InflowsWeekly moveup 5.2 percent
It made the five because of what happened to the rest of its sector in the same week.
Weekly move is each stock's movement during the window this issue analyzes (Week of October 8 to October 15, 2026), which closes before the issue publishes. It is not a return earned after publication. How each figure is measured →
What matters next
- Oct 21. Crown Castle reports third quarter results after the close, a date the company announced itself.
- Oct 27. The exchange offers on the Kenvue notes expire at 5:00 in the afternoon New York time, per the Kimberly-Clark filing.
- Oct 28. The Federal Reserve announces its decision at 2:00 in the afternoon eastern time, with no new economic projections.
You have the briefing.
Full research adds:
- the evidence behind the market read, and what would break it
- the complete case and the bear case on all five
- the next dated event for each name, and what result confirms or ends the thesis
- the primary sources every claim rests on
- the calls this issue is willing to be graded on next week
Full research
~22 minWeek ahead: the full analysis
I expect the average stock to keep beating the index for another week, and the reason is narrower than it sounds. What came apart this week was not belief in artificial intelligence, it was belief about who finances it. The companies that have to raise capital to build capacity were cut 10 to 18 percent, Dell down 17.61 percent, Super Micro 17.96 percent, Hewlett Packard Enterprise 17.42 percent, Arista 12.03 percent, Vertiv 11.89 percent and Micron 10.10 percent, while the two companies paying for the same buildout out of operating cash flow went UP, Microsoft 3.22 percent and Meta 2.20 percent. A market that had stopped believing in the technology sells both. A market working out who writes the cheque sells only one, and that is what I watched happen. Unwinds like that have not finished in four sessions before; the semiconductor index has now fallen seven straight. So from the October 15 close to the October 22 close I expect the equal weight S&P 500 to beat the cap weighted S&P 500 again. I put it at 68 percent, and I am holding it there rather than higher because of my own record, which I will put in front of you below: this is a continuation call on the newest move, and continuation calls on the newest move are one of the two ways I have been getting these wrong.
What would prove me wrong. I am wrong if the equal weight S&P 500 trails the cap weighted S&P 500 by more than 0.75 percentage points from the October 15 close to the October 22 close, measured as the percentage change in RSP minus the percentage change in SPY. The gap starts at zero and a normal week moves it about 1.27 points, so the line sits 0.59 of a standard deviation away. That is close enough for an ordinary week to reach, which is the point of putting it there. I put the odds of this view holding at 68%.
- Oct 21. Crown Castle reports third quarter results after the close, a date the company announced itself.
It is the first and only company test of the week's biggest winner, and the pick in this issue with the thinnest foundation. - Oct 27. The exchange offers on the Kenvue notes expire at 5:00 in the afternoon New York time, per the Kimberly-Clark filing.
Weak participation or an extension would say the financing of a 40 billion dollar plus acquisition is not as settled as this week implied. - Oct 28. The Federal Reserve announces its decision at 2:00 in the afternoon eastern time, with no new economic projections.
September inflation ran above expectations and long yields fell anyway; a hawkish read would put the long end back up and remove the tailwind under four of these five picks. - Oct 30. Regeneron reports third quarter results before the open, a date announced on September 24.
It separates a pipeline story from a selling story on the most expensive pick in the issue.
The biggest risk right now. This week was the capitulation rather than the beginning, and the artificial intelligence complex snaps straight back. Nothing that happened was a cash flow event. No customer cancelled an order and no large technology company cut its capital spending plans. A group of stocks gave up 12 to 18 percent in five sessions because of positioning and a story about the cost of debt, and positioning can reverse on nothing more than a calendar. Buying this particular dip has worked repeatedly through this cycle. If it works again the mechanics turn against me immediately, because the companies that fell ARE the largest weights in the index, so a snapback puts the cap weighted index back in front within days and takes the rotation bid out of all five of these picks at the same time. The technology sector fund XLK closing back above 200. It closed at 189.19 on October 15, so that is 5.71 percent higher, about 0.95 of a standard deviation of a ten session move, and getting there would mean the whole repricing was noise. I put it at 30% by 2026-10-29.
Last week I said, and I was wrong
I expected Constellation Energy to beat the utility sector fund XLU from October 9 to October 15, on the argument that a signed 20 year power agreement does not reprice because a private customer changed how it counts revenue. Constellation Energy fell 7.74 percent while XLU rose 0.58 percent. The argument was not wrong about the contract; it was wrong about what was being sold. The market was not re rating one company's accounting, it was re rating the whole artificial intelligence power theme, and a signed contract does not protect you from that. This is my second falsified call in a row, and four of my last five misses have been in the same direction, too bullish. The part I want you to hold me to is this: the biggest risk I published in that same issue was that the market had begun repricing artificial intelligence capital spending itself, confirmed by XLK closing below 190 by October 22. XLK closed at 189.19 on October 15. I named the thing that would break my call, gave it 30 percent, and made the call anyway. I said I would be wrong if Constellation Energy trailed the utility fund by more than 3.0 points. It trailed by 8.32. That is 5.32 points past my own line and 1.1 standard deviations beyond it, so there is no near miss to claim here and I am not going to dress it as one. For balance, all five of that issue's smaller watch items held, and across 45 of those I am running an 84 percent hit rate. The honest summary of my record is that the small dated calls are well calibrated and the one big weekly call is not yet.
This week's five
CCI, view score card · Crown Castle Inc. · Real Estate / Tower REITs
- Friday Five Score
- 82 / 100
- Move before publication
- +16.1%
- Actionability
- News Spike
- Next date
- Oct 21
On October 9 SpaceX agreed to buy a nationwide block of 800 MHz spectrum so Starlink Mobile can operate as a full American phone carrier, and said it intends to run its own ground equipment on towers, rooftops and other structures. A fourth national carrier needing tower space is the single best thing that can happen to a company that owns towers, and Crown Castle rose 15.60 percent that one day, finishing the week up 16.13 percent. It has gone nowhere in the four sessions since, which is worth knowing. I am putting it first and telling you straight away that it is the pick I am least sure of.
The catalyst. On October 9, 2026 SpaceX announced a definitive agreement to acquire the nationwide 800 MHz spectrum portfolio held by Grain Management, licences for up to 14 megahertz of paired low band spectrum that Grain had previously bought from T-Mobile, to let Starlink Mobile become a major American mobile carrier. SpaceX said it intends to operate standard wireless equipment such as antennas on towers, rooftops and other structures. The transaction is subject to approval by the Federal Communications Commission and other customary closing conditions, and SpaceX disclosed no value; reporting put it near 8 billion dollars. The Register, October 9, 2026
Why it made the five. It made the five because the evidence rules out the easy alternative explanation, and because it is the only one of these five that moved on its own news rather than on the rotation. Long rates fell 18 basis points this week, which helps every real estate investment trust, so I checked whether this was just a rate move: Prologis fell 1.82 percent and Equinix fell 1.47 percent in the same sector over the same days. A rate move lifts the sector, it does not single out towers. The decisive evidence is on the other side of the trade, where the three national carriers that are Crown Castle's largest customers fell hard, T-Mobile 8.34 percent, AT and T 5.51 percent and Verizon 4.21 percent. Lower rates would not do that. One event moved both sides in opposite directions on the same day, which is what a real catalyst looks like.
What to watch next. Oct 21: Crown Castle reports third quarter results after the close, with a call at 4:45 in the afternoon eastern time, a date the company announced itself. Confirms the thesis: Management talking about new carrier demand or site application volumes, which would start turning a third party announcement into something that shows up in bookings. Breaks it: A quarter that says nothing about new demand, which would leave the whole 16 percent resting on a regulatory filing nobody has ruled on yet.
The case against it. Crown Castle has signed nothing. The agreement is between SpaceX and a spectrum holder, Crown Castle is not a party to it, and the transaction still needs approval from the Federal Communications Commission. Worse for the thesis, SpaceX said it intends to roll out its own terrestrial infrastructure, and own can mean its own structures rather than leased space on somebody else's. So the market just paid 16 percent for a customer that has not agreed to be a customer. The one thing that softens it: after that move the shares are still 20 percent below their 52 week high and down 18.4 percent over a year, so the price is withdrawing part of a discount rather than paying a premium. That is a lower bar than the headline suggests, and it is the reason this is a pick rather than a warning.
Weekly move (before publication): +16.1%
Every CCI appearance →Track this pick on the Scoreboard →Size a position in it →
UNH, view score card · UnitedHealth Group Incorporated · Health Care / Managed Care
- Friday Five Score
- 88 / 100
- Move before publication
- +9.6%
- Actionability
- Fresh Breakout
- Next date
- Oct 15 to Dec 7
On October 13 UnitedHealth reported 112.7 billion dollars of revenue and adjusted earnings of 4.69 dollars a share against a consensus near 4.12, cut its medical care ratio to 88.4 percent from 89.9 percent a year earlier, and raised its full year outlook to at least 20.50 dollars a share. The same release said at least 69 percent of its members will sit in four plus Star Medicare Advantage plans for 2027. The stock rose 9.63 percent over the week and is my Stock of the Week.
The catalyst. UnitedHealth Group reported third quarter 2026 results on October 13, 2026: revenue of 112.7 billion dollars, earnings of 4.56 dollars a share and adjusted earnings of 4.69 dollars against a consensus near 4.12, a medical care ratio of 88.4 percent against 89.9 percent a year earlier, and operating cash flow of 5.1 billion dollars. Full year 2026 adjusted earnings guidance was raised to at least 20.50 dollars a share. The release also reported 2027 Medicare Advantage Star ratings with at least 69 percent of members in four plus Star plans and improvement in eleven of twelve quality measures. U.S. Securities and Exchange Commission, October 13, 2026
Why it made the five. It made the five because the attribution survives the obvious objection. Health care rose 5.37 percent as a sector, so some of this is rotation, but the timing separates the two: the shares went nowhere on the day of the release, closing at 377.76 against 378.52 the session before, and then rose 4.73 percent the next day, on October 14, which is the day the Nasdaq fell 1.88 percent. The market took a session to read the quarter and then paid for it on the day it was selling technology. The Star ratings matter more than the beat. A beat is one quarter; Star ratings set how much the government pays for a plan through 2027, and this one landed days before the enrollment period opened.
What to watch next. Oct 15 to Dec 7: Medicare annual enrollment for 2027 coverage is open, a statutory window rather than a company date, and it is where the Star ratings either turn into members or do not. Confirms the thesis: Early signs of membership moving toward the four plus Star plans, which is what converts a quality rating into revenue next year. Breaks it: Members staying put or drifting to competitors, which would mean the ratings were an operational win that nobody paid for.
The case against it. My own record says to be careful here, and I would rather say it than bury it. Across 35 matured picks, Beat and Raise is the weakest catalyst type I have published, averaging 1.43 percent BELOW the S&P 500 a month later. The mechanism is easy to see in this case: at 406.67 dollars the shares are 19.8 times the floor of the company's own raised outlook, and in a rotation week a defensive name gets paid twice, once for the number and once for being somewhere to hide. The second payment is the one that gets taken back when the rotation stops. The Star ratings also only convert into money if members actually choose the plans, and that is decided during enrollment, not in a press release.
Weekly move (before publication): +9.6%
Every UNH appearance →Track this pick on the Scoreboard →Size a position in it →
REGN, view score card · Regeneron Pharmaceuticals, Inc. · Health Care / Biotechnology
- Friday Five Score
- 76 / 100
- Move before publication
- +7.7%
- Actionability
- Extended
- Next date
- Oct 30
On October 12 Regeneron reported 84 week results from the extension of its Phase 3 OPTIMA trial of Pasatru in adults with fibrodysplasia ossificans progressiva, a rare condition in which soft tissue turns to bone. Between weeks 56 and 84 the treated patients formed zero new bone lesions, against nine detected by scan in the placebo group. Flare ups ran one at the higher dose against seventeen on placebo. The shares rose 7.68 percent.
The catalyst. On October 12, 2026 Regeneron released 84 week data from the Phase 3 OPTIMA extension study of Pasatru in adults with fibrodysplasia ossificans progressiva: zero new heterotopic ossification lesions between weeks 56 and 84 in treated patients, against nine new lesions detected by computed tomography in the placebo cohort, and one flare up at the 10 milligram per kilogram dose against fourteen at 3 milligrams per kilogram and seventeen on placebo. Safety through 84 weeks was consistent with the earlier phases with no deaths reported. Pasatru was approved in August 2026 and is the first approved treatment for the condition. Clinical Trials Arena, October 13, 2026
Why it made the five. It made the five on the strength of the result rather than the strength of the attribution, and I want to be precise about which, because this is the weakest case in the issue. Zero is a rare word in clinical data, and this is the first approved treatment for a condition that previously had none. But health care rose 5.37 percent as a sector, and on the two days Regeneron did its work, October 14 and 15, it beat its own sector by only 0.8 and 0.5 percentage points. Measured honestly, about six of its 7.68 percent is the health care bid and roughly two points is Regeneron. I am including it because the week's lesson is the difference between confirmed and projected, and this is the cleanest confirmation in the issue: a drug already approved in August, doing at 84 weeks what it did at 56. If you want the pick in this issue with the least company-specific evidence behind its move, it is this one.
What to watch next. Oct 30: Regeneron reports third quarter results before the open, with a call at 8:30 in the morning eastern time, a date the company announced on September 24. Confirms the thesis: Commercial numbers that show the newer approvals are selling, which is what justifies paying 92.7 percent of a 52 week high. Breaks it: A quarter carried by the older franchise with the pipeline still all promise, which would make this week's move purely sector rotation.
The case against it. This is the weakest attribution of the five and the most expensive stock in it. The data is confirmatory on an already approved drug, and the condition is ultra rare, so there is no plausible way this readout re rates a company of this size on its own. The shares sit at 92.7 percent of their 52 week high after rising 39.9 percent over the year, which leaves the least room of any pick here for a disappointment. One thing that looks alarming and is not: the co chief scientific officer sold roughly 13 million dollars of stock on October 13 and 14, in the exact sessions the data moved the shares. The filing shows those sales ran through a trading plan arranged in advance and were paired with an option exercise, so it was a scheduled transaction, not a verdict on the news. He kept 47,833 shares.
Weekly move (before publication): +7.7%
Every REGN appearance →Track this pick on the Scoreboard →Size a position in it →
KMB, view score card · Kimberly-Clark Corporation · Consumer Staples / Household Products
- Friday Five Score
- 84 / 100
- Move before publication
- +6.5%
- Actionability
- Fresh Breakout
- Next date
- Oct 27
Two things happened to the Kenvue acquisition on October 13 and they happened on the same day. European regulators cleared the deal, on the condition that Kimberly-Clark sells its entire European tampon and feminine hygiene business, including Kotex. Separately the company filed results of the early tender on the exchange of Kenvue's bonds, the step that sorts out the debt. The market's first reaction was to do nothing at all: the shares fell 0.49 percent that session. Then on October 15 they rose 4.69 percent, finishing the week up 6.48 percent.
The catalyst. On October 13, 2026 the European Commission granted conditional clearance to the Kimberly-Clark acquisition of Kenvue, requiring Kimberly-Clark to divest its entire European Economic Area tampon and feminine hygiene portfolio including Kotex, Camelia and Record, after the Commission identified competition concerns in the Czech Republic, Estonia and Slovakia; Dilek Gida Uretim agreed to buy the divested assets. The same day Kimberly-Clark filed a Form 8-K reporting early tender results for the exchange offers and consent solicitations on the Kenvue notes, stating the acquisition is expected to close in the fourth quarter of 2026, that the exchange offers expire at 5:00 in the afternoon New York time on October 27, 2026, and that settlement is not anticipated before November 2, 2026. U.S. Securities and Exchange Commission, October 13, 2026
Why it made the five. It made the five because of what that delayed reaction looks like when you measure it properly. On October 15, the day the rotation hit, consumer staples as a sector rose 0.72 percent and Kimberly-Clark rose 4.69 percent, so roughly four points of that day was the company and not the sector. The news was two days old by then, which is the interesting part: the market read a conditional clearance and a bond tender, decided it needed a day to think, and then paid for it. An acquirer rising on its own deal being approved is unusual in itself, because normally the buyer drifts on clearance. Rising tells you the price had been carrying real risk that the deal would be blocked or cost too much to fund, and that some of that risk has now come out.
What to watch next. Oct 27: The exchange offers on the Kenvue notes expire at 5:00 in the afternoon New York time, a deadline stated in the company's own filing. Confirms the thesis: High participation and the indenture amendments carrying, which clears the financing path to a fourth quarter close. Breaks it: An extension or weak participation, which would say bondholders want better terms and the funding is not settled after all.
The case against it. Clearance is the easy part and it was not even unconditional. Kimberly-Clark has to find a buyer for its European feminine hygiene brands and complete that sale, and a remedy that falls through puts the approval back in play. This clearance also covers Europe and not every other jurisdiction. Then comes the actual problem, which is integration: this is a consumer health acquisition of more than 40 billion dollars, financed partly in stock, which means more shares outstanding, being executed by a company whose own shares are down 13.1 percent over the past year. Nothing about this week tells you the combined company will work. It only tells you it is more likely to exist.
Weekly move (before publication): +6.5%
Every KMB appearance →Track this pick on the Scoreboard →Size a position in it →
BLK, view score card · BlackRock, Inc. · Financials / Asset Management
- Friday Five Score
- 86 / 100
- Move before publication
- +5.2%
- Actionability
- Extended
On October 14 BlackRock reported 15.488 trillion dollars under management, a record, with 205.5 billion dollars of new money arriving in the quarter alone. Revenue rose 19 percent and adjusted earnings rose 38 percent. The number I care about most is the dullest: fee revenue from existing clients grew 11 percent, the ninth quarter running at or above the company's own 5 percent long term target. The shares rose 5.20 percent.
The catalyst. BlackRock reported third quarter 2026 results on October 14, 2026: assets under management of 15.488 trillion dollars, a record, with quarterly net inflows of 205.5 billion dollars; organic base fee growth of 11 percent annualised, a ninth consecutive quarter at or above the company's 5 percent long term target; diluted earnings of 10.57 dollars a share, up 25 percent year over year, and adjusted diluted earnings of 15.93 dollars, up 38 percent; and revenue of 7.752 billion dollars, up 19 percent from 6.509 billion, with technology services revenue up 14 percent. U.S. Securities and Exchange Commission, October 14, 2026
Why it made the five. It made the five because of what happened to the rest of its sector in the same week. Bank of America fell 3.56 percent, Citigroup 3.80 percent, Morgan Stanley 2.85 percent and State Street 4.28 percent, all around their own reports. So this was not a bid for financials, it was a bid for this company's results. The timing is worth stating accurately: the shares added only 0.72 percent on the day of the release and then 4.38 percent on October 15, against 1.38 percent for the financial sector that day, so about three points of that session was BlackRock and not its sector. It also fits the week exactly: in a week the market stopped paying for companies building artificial intelligence capacity, it paid for the company that collects a fee on everyone's allocation decision regardless of who wins.
What to watch next. No fourth quarter reporting date has been announced yet, so I am not going to invent one. The thing to watch instead is whether organic fee growth holds above 5 percent when it is next disclosed. Confirms the thesis: A tenth consecutive quarter above the long term target, which would make the growth structural rather than a bull market artefact. Breaks it: Fee growth slipping back toward market returns, which would confirm the market is right to treat this as a cyclical peak.
The case against it. Fee revenue is a percentage of asset values, which means a sustained fall in markets cuts the base that produced the record, and no amount of good management offsets that. There is also a question the stock itself is asking: after a record quarter the shares are still DOWN 4.3 percent over the past year, and they only rose 5.20 percent on this news. The market is treating 15.488 trillion dollars as a cyclical peak rather than a new floor. It may be right. The 11 percent organic fee growth is the part that is not simply market direction, and it is the number that settles the argument one way or the other over the next few quarters.
Weekly move (before publication): +5.2%
Every BLK appearance →Track this pick on the Scoreboard →Size a position in it →
Stock of the week
UnitedHealth Group Incorporated (UNH, view score card)
Stock of the Week is the most instructive name in the issue, not the largest weekly mover.
This week the market stopped paying for numbers companies hope to earn and paid for numbers already banked, and UnitedHealth is the cleanest example of the second kind. A quarter that beat, a full year outlook raised to at least 20.50 dollars a share, a medical care ratio down a point and a half, and Medicare quality ratings that set what the government pays through 2027. The telling detail is that the shares did nothing on the day of the release and then rose 4.73 percent the following session, which happened to be the day the Nasdaq fell 1.88 percent. The market read the quarter, and then paid for it with money it took out of technology. I am also telling you the uncomfortable part: across 35 matured picks, a beat and a raise is historically my weakest catalyst, so a good number is the start of the case and not the end of it.
Sector rotation
Into: Health Care · Consumer Staples · Real Estate · Materials
Out of: Technology · Industrials · Communication Services · Utilities
Rotation is money moving between industry groups. It shows where big investors added this week and where they pulled back.
Terms in this issue
Equal Weight Index. An index that gives every company the same weight instead of weighting by size, so a 500 company equal weight index holds the same amount of the smallest member as the largest. Comparing it to the normal version tells you whether a move came from a few giants or from the whole market. More in the Learn hub →
Medical Care Ratio. The share of the premium money a health insurer collects that it pays back out in medical claims. A lower ratio means more of each premium dollar stays with the insurer, so a drop of a point or two is a large profit swing.
Merger Remedy. A business a buyer agrees to sell off so competition regulators will approve its acquisition. The approval depends on the sale actually completing, so a remedy that falls apart can reopen a deal everyone thought was cleared.
Organic Base Fee Growth. For an asset manager, the growth in fee income that comes from clients adding money rather than from markets going up. It separates what the business did from what the market did for it.
Spectrum Licence. Government permission to use a specific slice of the radio airwaves in a specific place. Low frequency slices like 800 MHz travel further and reach inside buildings, which is why they are the most valuable kind for a phone network.
Falsifier. The specific thing I say in advance would prove my forecast wrong, written so a reader can check it against market prices rather than take my word for it. If it happens, I publish that I was wrong.